Yongxiang Xia

机构：Nanjing University of Chinese Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing Medical University · ORCID：0000-0001-6589-797X

发表论文 83 篇 · 总被引 3641 次 · h-index 28

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 516)
• Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma (2023 · Journal of Hepatology · 被引 153)
• PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022 · Nature Communications · 被引 125)
• Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma (2023 · Journal for ImmunoTherapy of Cancer · 被引 59)
• The Ninj1/Dusp1 Axis Contributes to Liver Ischemia Reperfusion Injury by Regulating Macrophage Activation and Neutrophil Infiltration (2023 · Cellular and Molecular Gastroenterology and Hepatology · 被引 52)
• Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy (2022 · Journal for ImmunoTherapy of Cancer · 被引 37)